1. SGLT2 Inhibitors and CV Outcomes

3. Introduction to SGLT2 Inhibitors

4. EMPA-REG OUTCOME and CANVAS CVOTs

5. EMPA-REG OUTCOME Trial Design

6. CANVAS and CANVAS-R Trial Design

7. EMPA-REG OUTCOME and CANVAS Demographics

8. Heart Failure and Diabetes

9. EMPA-REG OUTCOME and CANVAS Results

10. DECLARE-TIMI58 and VERTIS-CV Demographics

11. DECLARE-TIMI58 and VERTIS-CV Outcome Measures

12. CANVAS Analysis of 2 Subgroups

13. EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI58 , VERTIS-CV

14. Interpreting CVOT Data Into Clinical Practice

15. EMPA-REG OUTCOME and CANVAS Safety

16. EMPA-REG OUTCOME and CANVAS Lower Limb Amputations

17. CANVAS Subanalysis Heart Failure

18. EMPA-REG OUTCOME Subanalysis Peripheral Artery Disease

19. Clinical Application

20. When to Start an SGLT2 Inhibitor?

21. Concluding Remarks

22. Abbreviations